KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.

Blood · 2025-Jun-05 · PMID 40009494

Panel B提取完成待 EXE 对齐验证

OS

Figure 2. Kaplan-Meier estimates of efficacy end points by MRD∗ response status at EOT in the overall intent-to-treat population. (A) PFS; (B) OS. Fisher’s exact test was performed to compare MRD status at EOCT and EOT. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10 –4 ]) and MRD + (≥10 –4 ).

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T17:46:35+00:00